This small, retrospective study looked at 40 male patients with VEXAS syndrome to understand how different treatments affect the disease. The researchers tracked clinical features, treatment responses, and survival outcomes over time.
The study found that hypomethylating agents (HMA) were associated with a gradual and sustained increase in clinical and biological responses. Specifically, about 83.3% of patients showed a global response, which included both complete and partial responses. Additionally, certain genetic mutations, such as c.209T>A, were linked to milder symptoms like less severe anemia.
However, there are important reasons to be cautious. The study was small, and the data on overall survival is still immature. Researchers noted that the findings need to be validated in much larger groups of people. The study also noted that gastrointestinal involvement was linked to a poorer prognosis.
While these results are encouraging for the potential role of HMA in managing VEXAS syndrome, they are early observations. Patients should discuss any treatment changes or concerns with their medical specialists.